Literature DB >> 23421407

Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005.

Helena Filipsson Nyström1, Svante Jansson, Gertrud Berg.   

Abstract

OBJECTIVES: To study hyperthyroidism in long-term iodine sufficiency (IS), as iodine supply affects its occurrence.
DESIGN: Prospective descriptive study. PATIENTS: In 2003-2005, all referred cases of subclinical (SH) and overt hyperthyroidism (OH) were registered at diagnosis from a population (n = 631 239) in Gothenburg, Sweden. MEASUREMENTS: Information on age, gender, smoking, thyroid associated ophthalmopathy (TAO), thyroid hormones and TSH receptor antibodies (TRab) was collected. Incidences were calculated. SH and OH cases with Graves' disease (GD), toxic multinodular goiter (TMNG) and solitary toxic adenoma (STA) were compared. In GD, TRab+ and TRab- cases and patients with (TAO+) and without TAO (TAO-) were compared.
RESULTS: The total incidence (n/100 000/year) of hyperthyroidism was 27·6; OH 23·8; SH 3·8; GD 21·4; TMNG 4·3; and STA 1·8. SH was more common among TMNG (40·2%) and STA (45·7%) than in GD (5·9%). SH-GD patients were older, more often smokers and had lower TRab levels than OH-GD patients. FreeT4 and T3 levels in GD were higher than in TMNG and STA. FreeT4, T3 and TRab decreased with age in patients with GD, P < 0·0001. TRab- patients had lower T3 than TRab+ patients, P < 0·001. TRab was positively correlated to FreeT4, P < 0·0001. TAO occurred in 20% of patients with GD. TAO+ patients were younger than TAO- patients. Smokers did not have more TAO.
CONCLUSION: The total incidence of hyperthyroidism was low. GD dominated with an age-related decline of thyroid hormones and TRab levels. The spectrum of hyperthyroidism in this long-term IS area may represent the future situation for countries with shorter history of IS.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23421407     DOI: 10.1111/cen.12060

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  35 in total

Review 1.  Diagnosis and management of Graves disease: a global overview.

Authors:  Luigi Bartalena
Journal:  Nat Rev Endocrinol       Date:  2013-10-15       Impact factor: 43.330

Review 2.  Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Authors:  Christoph Langenstein; Diana Schork; Klaus Badenhoop; Eva Herrmann
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

Review 3.  Role of genetic and non-genetic factors in the etiology of Graves' disease.

Authors:  M Marinò; F Latrofa; F Menconi; L Chiovato; P Vitti
Journal:  J Endocrinol Invest       Date:  2014-11-25       Impact factor: 4.256

Review 4.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

5.  Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves' disease.

Authors:  Brian Hung-Hin Lang; Yu-Cho Woo; Keith Wan-Hang Chiu
Journal:  Eur Radiol       Date:  2019-06-17       Impact factor: 5.315

6.  Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.

Authors:  L Scappaticcio; M Castellana; C Virili; G Bellastella; M Centanni; S Cannavò; A Campennì; R M Ruggeri; L Giovanella; P Trimboli
Journal:  J Endocrinol Invest       Date:  2019-08-26       Impact factor: 4.256

Review 7.  Global epidemiology of hyperthyroidism and hypothyroidism.

Authors:  Peter N Taylor; Diana Albrecht; Anna Scholz; Gala Gutierrez-Buey; John H Lazarus; Colin M Dayan; Onyebuchi E Okosieme
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

Review 8.  Hyperthyroidism.

Authors:  Simone De Leo; Sun Y Lee; Lewis E Braverman
Journal:  Lancet       Date:  2016-03-30       Impact factor: 79.321

Review 9.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

10.  2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.

Authors:  George J Kahaly; Luigi Bartalena; Lazlo Hegedüs; Laurence Leenhardt; Kris Poppe; Simon H Pearce
Journal:  Eur Thyroid J       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.